Analytical Data
-
基因名
VEGFR-2
-
简介
VEGFR-2 protein is a tyrosine protein kinase receptor for VEGFA, VEGFC and VEGFD and is critical in angiogenesis, blood vessel development and embryonic hematopoiesis. It promotes endothelial cell function and actin cytoskeletal reorganization. VEGFR-2 Protein, Human (Biotinylated, HEK293, mFc) is the recombinant human-derived VEGFR-2 protein, expressed by HEK293 , with C-mFc labeled tag.
- Application
-
别名
CD309; KDR; VEGFR; VEGFR2; VEGFR-21; FLK1; KRD1; Ly73
-
种属
Human
-
表达系统
HEK293
-
标签
C-mFc
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P35968-1
-
表达区间
A20-E764
-
蛋白长度
Extracellular Domain
-
分子量
135-160 kDa,based on Bis-Tris PAGE under reducing conditions,due to the glycosylation.
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2) is a key receptor in the vascular system, primarily involved in angiogenesis, the process by which new blood vessels form from pre-existing ones. This receptor is activated by binding to its primary ligand, VEGF, which plays a pivotal role in physiological and pathological processes, including tumor growth and metastasis. The study of VEGFR-2 is crucial due to its implications in cancer therapy, where its overexpression is commonly associated with malignant progression and poor patient outcomes. Researchers have been focusing on developing recombinant VEGFR-2 proteins to better understand its structure, function, and interactions within signaling pathways. These recombinant proteins serve as critical tools for elucidating the mechanisms of angiogenesis and identifying potential therapeutic targets. By generating VEGFR-2 in a heterologous expression system, scientists can produce large quantities of the protein for biochemical assays and structural studies. This research aids in the design of novel anti-angiogenic drugs, including monoclonal antibodies and small molecule inhibitors, which aim to block VEGFR-2 signaling and inhibit tumor angiogenesis. Additionally, studying VEGFR-2 can help in the exploration of potential biomarkers for disease prognosis and treatment responses. Overall, the ongoing research on VEGFR-2 recombinant proteins holds great promise for advancing cancer therapies and improving clinical outcomes for patients with angiogenesis-related diseases.
